Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer

作者：Oostra Drew R; Lustberg Maryam B^*; Reinbolt Raquel E; Pan Xueliang; Wesolowski Robert; Shapiro Charles L

来源：Molecular and Cellular Endocrinology, 2015, 402(C): 51-56.

DOI：10.1016/j.mce.2014.12.028

• Breast cancer
• Osteoprotegerin
• Ovarian failure
• Chemotherapy
• Bone loss

Purpose: Chemotherapy induced ovarian failure (CIOF) results in rapid bone loss. Receptor Activator of Nuclear Factor Kappa-B (RANK)-RANK ligand (RANK-L) signaling balances bone resorption and formation. Osteoprotegerin (OPG) acts as a decoy receptor for RANK, interrupting osteoclast activation and bone resorption. This study examined the relationship between OPG and bone loss in women with CIOF.
Methods: Premenopausal women with stage I/II breast cancers receiving adjuvant chemotherapy were evaluated at chemotherapy initiation, 6 and 12 months. Bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN), follicle stimulating hormone (FSH), ionized calcium, osteocalcin, and OPG were serially measured. CIOF was defined as a negative pregnancy test, FSH levels >30 MIU/mL, and >= 3 months of amenorrhea.
Results: Forty women were enrolled; 31 (77.5%) met CIOF criteria. BMD significantly decreased (p < 0.001) in the CIOF group at both time points: LS BMD decreased from a median of 0.993 g/cm(2) to 0.976 g/cm(2) and 0.937 g/cm(2) at 6 and 12 months, respectively. OPG was significantly elevated at 6 months (median increase 0.30 pmol/L, p = 0.015) and then decreased at 12 months to levels still above baseline (median difference 0.2 pmol/L, p = 0.70).
Conclusions: In what was likely a compensatory response to rapid bone loss, CIOF patients' OPG levels increased at 6 months and then decreased at 12 months to values greater than baseline assessments.
This phenomenon is described in other diseases, but never before in CIOF.

• 出版日期2015-2-15